ReviewFrontiers in cellular and infection microbiology2023
The role of short-chain fatty acids produced by gut microbiota in the regulation of pre-eclampsia onset.
Review in Frontiers in cellular and infection microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Role of microbial metabolites in the pathogenesis of hypertensive disorders of pregnancy: From short‑chain fatty acids to tryptophan metabolites (Review).Molecular medicine reports · 2026Review
- Towards microbiome-informed strategies for predicting and preventing pregnancy complications.Reproduction & fertility · 2026Review
- Control of HELLP syndrome and pre-eclampsia with microbiota.Molecular biology reports · 2026Review
- The maternal and infant gut microbiome: implications for pregnancy outcomes, immune development, and health in the first 1000 days.Journal of translational medicine · 2026Review
- Microbiome, Epigenetics, and Nutritional Factors in Shaping Perinatal Pregnancy Outcomes.International journal of molecular sciences · 2026Review
- Review
- Gut-placenta axis: gut microbiota metabolites may play a role in regulating maternal-fetal immune tolerance and the pathogenesis of adverse pregnancy outcomes.Frontiers in immunology · 2026Review
- Trends and regional disparities in maternal hypertensive disorders among women of childbearing age: a global burden of disease analysis from 1990 to 2021.BMC pregnancy and childbirth · 2025Article
- Investigating the Microbiome in Relation to Mental Distress Across Two Points During Pregnancy: Data From U.S. and Swedish Cohorts.Biological psychiatry global open science · 2025Article
- Enhanced Bioactivity of FermentedCurrent issues in molecular biology · 2025Article
- A Review of Dietary and Lifestyle Management of Pre-Eclampsia and Postpartum Eclampsia.Preventive nutrition and food science · 2025Review
- The gut-placenta axis in preeclampsia: unraveling the regulatory network and clinical prospects in pathogenesis.Frontiers in cellular and infection microbiology · 2025Review
- Association of placental manganese levels, maternal gut microbiota, and preeclampsia: a tripartite perspective.Frontiers in microbiology · 2025Article
- The Hidden Relationship between Intestinal Microbiota and Immunological Modifications in Preeclampsia Pathogenesis.International journal of molecular sciences · 2024Review
- Placental Epigenome Impacts Fetal Development: Effects of Maternal Nutrients and Gut Microbiota.Nutrients · 2024Review
- Reducing the Risk of Pre-Eclampsia in Women with Polycystic Ovary Syndrome Using a Combination of Pregnancy Screening, Lifestyle, and Medical Management Strategies.Journal of clinical medicine · 2024Review
- Article
- From gut to placenta: understanding how the maternal microbiome models life-long conditions.Frontiers in endocrinology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Preeclampsia (PE) is a common pregnancy-related disorder characterized by disrupted maternal-fetal immune tolerance, involving diffuse inflammatory responses and vascular endothelial damage. Alterations in the gut microbiota (GM) during pregnancy can affect intestinal barrier function and immune balance. Aims and purpose: This comprehensive review aims to investigate the potential role of short-chain fatty acids (SCFAs), essential metabolites produced by the GM, in the development of PE. The purpose is to examine their impact on colonic peripheral regulatory T (Treg) cells, the pathogenic potential of antigen-specific helper T (Th) cells, and the inflammatory pathways associated with immune homeostasis. Key insights: An increasing body of evidence suggests that dysbiosis in the GM can lead to alterations in SCFA levels, which may significantly contribute to the development of PE. SCFAs enhance the number and function of colonic Treg cells, mitigate the pathogenic potential of GM-specific Th cells, and inhibit inflammatory progression, thereby maintaining immune homeostasis. These insights highlight the potential significance of GM dysregulation and SCFAs produced by GM in the pathogenesis of PE. While the exact causes of PE remain elusive, and definitive clinical treatments are lacking, the GM and SCFAs present promising avenues for future clinical applications related to PE, offering a novel approach for prophylaxis and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.